… This large population-based study suggests erlotinib efficacy might be linked with gastric pH
… coadministration of erlotinib with AS therapy. Further prospective investigation is warranted. …

… interactions that may alter the safety or efficacy of therapy. … the frequency of acid-suppression
therapy use with erlotinib and … events in patients receiving erlotinib as standard of care. …

… In this study, concurrent use of AS did not affect the efficacy or toxicity of erlotinib and
gefitinib in patients with advanced NSCLC harboring EGFR mutations. It provides data that can …

… Our study raises the possibility that AS use may have less effect erlotinib concentrations
and efficacy in the general population then may have been predicted by the single-dose PK …

… Erlotinib exposure was reduced by ∼15% Erlotinib should be taken 10 h after H2-… compromise
therapeutic efficacy in some individuals. Due to the persistent acid suppression of proton-…

… is not associated with decreased efficacy of gefitinib and erlotinib in patients with mutated …
that gastric acid suppression was associated with decreased erlotinib efficacy in NSCLC …

… Erlotinib shows pH-dependent solubility and its absorption is decreased in patients receiving
gastric acid suppression therapy. Here, we examined whether administration of erlotinib in …

… , erlotinib avoids the normal tissue toxicity inherent to cytotoxic agents, eg, hematologic
suppression, … Preliminary efficacy of erlotinib has also been demonstrated in phase II trials in …

… This study showed that antacids negatively affected the efficacy of erlotinib in both PFS (HR:1.83,
1.4 vs 2.3 months, p<0.001) and OS (HR:1.37, 12.9 vs 16.8 months, p=0.003) [21]. …

… erlotinib and acid-suppressive agents was shown to be associated with decreased erlotinib
efficacy … Because a PPI often is indicated during erlotinib therapy, pharmacists and medical …